The effects of 15-and 5-ml doses of magnesium-aluminum hydroxide (MAH) and calcium carbonate (CC) antacids, respectively, on the bioavailability of ofloxacin after single oral 400-mg doses of ofloxacin were investigated in a 32-subject, randomized, crossover, open-label study. On four separate occasions, subjects received ofloxacin alone or antacid 24 h before, 2 h before, or 2 h after ofloxacin administration (n = 16 for each antacid). CC administration had no significant effect on the rate and extent of ofloxacin absorption regardless of the timing of antacid administration. A small but significant negative effect of MAH administration 2 h before ofloxacin administration was noted as evidenced by area under the curve and peak concentration in plasma data. Simultaneous administration of ofloxacin with either antacid was not investigated in this study. It appears that MAH and CC antacids in the doses used in this study generally do not interfere in a clinically significant manner with the bioavailability of ofloxacin, provided that an interval of at least 2 h separates the administration of these products.
Ofloxacin is a synthetic carboxyquinolone antimicrobial agent which exhibits broad-spectrum in vitro bactericidal activities against gram-positive and gram-negative aerobes (8) . The clinical efficacy of ofloxacin has been documented in patients with respiratory tract, upper and lower urinary tract, gonococcal and nongonococcal urethritis, and skin and soft tissue infections (8, 14) .
Coadministration of some antacids and sucralfate has resulted in diminished absorption of several of the carboxyquinolones. This phenomenon has been reported to be due to the formation of insoluble chelates in the gastrointestinal tract (5) (6) (7) (9) (10) (11) (12) . Although the majority of these interaction studies have investigated the quinolone ciprofloxacin, four reports have suggested the existence of a similar interaction between antacids and ofloxacin (7, 12 This study was designed to rigorously characterize the interaction potential between ofloxacin and two commonly used antacid preparations: (i) magnesium-aluminum hydroxide (Maalox; Rorer Pharmaceutical Corp., Fort Washington, Pa.) and (ii) calcium carbonate (Titralac; 3M Riker, St. Paul, Minn.).
The study was approved by the Human Subjects Research Committee, Hennepin County Medical Center. Thirty-two normal, healthy male volunteers who participated in the study were between the ages of 18 and 40 years, and all subjects gave written, informed consent prior to participation. The patients were healthy, as determined by comprehensive medical history, physical examination, electrocardiography, and laboratory profiles. None of the subjects was taking medications within 1 week before or during the study. None of the subjects had a history or current evidence of * Corresponding author. significant renal, hepatic, cardiovascular, hematologic, neurologic, psychiatric, respiratory, or metabolic disease.
A parallel study design was followed wherein 16 subjects were randomly assigned to receive single doses of ofloxacin (2 x 200 mg, lot 4007; Ortho Pharmaceutical Corporation, Raritan, N.J.) and calcium carbonate (5 ml) and 16 were to receive single doses of ofloxacin (2 x 200 mg) and magnesium-aluminum hydroxide (15 ml). The assignment of study phase ordering was achieved by using a Latin square design. In both study arms, all patients received 400 mg of ofloxacin alone (regimen 1), ofloxacin preceded 2 h by antacid administration (regimen 2), ofloxacin followed 2 h later by antacid administration (regimen 3), and ofloxacin preceded 24 h by antacid administration (regimen 4). All subjects were fasted for at least 8 h prior to and for 1 h following administration of the second component of each regimen. Use of antacids, bismuth subsalicylate, or other gastrointestinal preparations at any time during the study period was prohibited. Study phases were separated by washout periods of at least 4 days.
Blood samples of 5 ml were obtained just prior to ofloxacin administration and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 h following ofloxacin administration. Plasma was separated via centrifugation and stored frozen at -20°C until analysis.
The concentration of ofloxacin in plasma was determined by a high-pressure liquid chromatography method. After extraction at pH 7 with dichloromethane, the extract was injected onto a Cl8 ,uBondapak column (25 cm by 4.6 mm [inner diameter]; Waters Associates Inc., Milford, Mass.). The mobile phase consisted of 1.74 g of potassium dihydrogen phosphate and 20 mg of 1-hexanesulfonic sodium salt (Eastman Kodak Co., Rochester, N.Y.) dissolved in 650 ml of distilled water, combined with 350 ml of methanol, and adjusted to pH 3 with phosphoric acid. The imidazolic derivative of ofloxacin (Daiichi Seiyaku) was used as the internal standard. Detection was done with a UV detector at 313 nm. The limit of quantitation was 0.01 mg/liter, and the extraction efficiency was greater than 95%. The assay was linear over the concentration range of 0.025 to 9 mg/liter. The intra-and interday coefficients of variation ranged from Hours after administration (13) and Cohen (2) . All statistical evaluations were performed by using the Statistical Analysis System (SAS Institute, Raleigh, N.C.) (1). Statistical significance was assessed at the 5% level.
Fifteen of 16 and 14 of 16 subjects in the calcium carbonate and magnesium-aluminum hydroxide treatment groups, respectively, completed the entire study. The dropouts occurred for personal or administrative reasons unrelated to the study. The mean plasma concentration-versus-time profiles for the calcium carbonate and magnesium-aluminum hydroxide treatment groups are depicted in Fig. 1 and 2 1.0, 3.7 + 0.9, 3.8 ± 0.9 and 3.5 ± 0.9 mg/liter, respectively; P < 0.05) ( Table 2 ). In addition, the Tmax was significantly longer in regimen 2 than in regimens 3 and 4 (2.0 ± 0.7, 1.5 ± 0.5, 1.5 ± 0.5 h, respectively; P < 0.05). The minimum detectable differences with 80% power for AUC0. 
